MedPath

Tonometry (1) and duplex ultrasound (2) to predict Abdominal Aorta Aneurysm (3) progression and cardiovascular events in aneurysm patients

Completed
Conditions
10082206
10002363
Enlargement of the large blood vessel (aorta)/aneurysm
Registration Number
NL-OMON48372
Lead Sponsor
Rijnstate Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
167
Inclusion Criteria

1. Male or female at least 18 years old;
2. Informed consent form understood and signed and patient agrees to follow-up visits;
3. Has an abdominal aortic aneurysm (AAA), who is still under surveillance;

Exclusion Criteria

1. Life expectancy < 2 years;
2. Psychiatric or other condition that may interfere with the study;
3. Participating in another clinical study, interfering on outcomes;
4. Increased risk for coronary spams (score Rose-questionnaire *2);
5. Presence of Raynaud*s phenomenon, chronic pain syndrome at upper extremity(s), presence of an AV fistula or shunt, open wounds to the upper extremity(s), and/or scleroderma associated with placing the hand in ice water;
6. Recent (<3 months) presence of angina pectoris, myocardial infarction, cerebral infarction, and/or heart failure, or PAD treatment

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study endpoint is the incidence of MACE during two year follow-up<br /><br>(Major adverse cardiovascular events (MACE); including myocardial infarction,<br /><br>cerebral infarction, heart failure, and peripheral vascular disease).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The following secondary endpoints will be evaluated during the 2-year follow-up:<br /><br>- SMART risk score;<br /><br>- SphygmoCor parameters;<br /><br>o Peripheral pressure measurements (PWA)<br /><br>o Central and abdominal pressure parameters (derived using a transfer function)<br /><br>(PWA)<br /><br>o Cardiac output parameters (SEVR, ED) (PWA)<br /><br>o PWV<br /><br>-CAR-test results;<br /><br>o Percentage of vasodilatation/vasoconstriction to the CAR-test at the common<br /><br>carotid artery at baseline.<br /><br>o Magnitude and timing of the blood flow and perfusion response<br /><br>o Blood pressure and heart rate responses<br /><br>-AAA progression (in mm/year);<br /><br>-AAA repair;<br /><br>-AAA Rupture;<br /><br>-Any other (S)AE ;<br /><br>-Score EQ-5D questionnaire<br /><br>-Score IPQ-K questionnaire</p><br>
© Copyright 2025. All Rights Reserved by MedPath